New CEO at Deinove
Rideau is considered to be very experienced in the development, negotiation and implementation of strategic partnerships in the life sciences field, particularly in microbiology applied to health and infectious diseases. Prior to joining the French biotech company, Rideau was in charge of developing industrial relations and coordinating the strategic partnership team at Bioaster (Lyon/Paris), a Technology Research Institute in applied microbiology, which specialises in the design and use of technology innovations in the field of microbiology.
Rideau initiated and implemented structuring partnerships, technologically and financially, with major French and international players (Takeda Pharmaceuticals, Bio-Rad Laboratories, bioMérieux, Boehringer Ingelheim, etc.), SMEs (Kaleido Biosciences Inc., Enterome, MaaT Pharma, LNC Therapeutics, Biofilm Pharma, etc.) and academic institutions (INRAE MetaGenoPolis, Institut Pasteur, CNRS, etc.). Before that, Rideau held various positions in companies like Library House Ltd, Bionest Partners and Glaizer Group, MorphoSys AG or Bio-Rad Laboratories.
Rideau holds a PhD in Molecular and Cellular Biology (University of Cambridge, England), a European Magistère in Genetics and an MSc in Cellular and Molecular Genetics (Paris Diderot University and Sorbonne University), as well as an MBA in International Management (ESCP Europe).
Deinove was founded in 2006. The French biotech company is developing new-generation anti-infective agents and is preparing to enter a first antibiotic candidate into Phase II. The second area of expertise are bioactive ingredients of natural origin for cosmetic products and with potential for applications in health and nutrition.